Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Rallybio is driven by the passion and experience of scientists and healthcare providers who are dedicated to the development of novel therapies. We are advancing transformative cell and gene therapies to enable cures for diseases that affect patient lives.

Rallybio's mission is to accelerate the development of life-changing therapies and improve the lives of patients and their families. We strive to empower patients with access to innovative treatments that are truly transformative.

Rallybio is grateful to have been recognized for our mission and efforts. In 2020, we were honored to be named a top 10 life sciences company in 2020 by the CB Insights Global Life Sciences report. We were also named one of SiliconValley Business Journal's Fast 100 winners.